European Commission decision to approve the pediatric use of the antifungal Cresemba® (isavuconazole) and to extend market exclusivity triggers milestone payment of CHF 10 million to Basilea
Basilea Pharmaceutica AG, Allschwil Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 27, 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), a biopharmaceutical company focused on the needs…
